The current blustery economic
recession created, not a drop in pressure, but a drop in industry growth.
In prior years, a billion dollar industry expanding its growth at about 10% per
year did not need to worry about small niche markets or tiny fifty-million
dollar areas of market growth. With pharmaceutical companies fighting for
market share and growth, times have dramatically changed.
Concurrently sweeping across the
country is a jet stream of demographic change. The 2010 census results
reported for the first time the US had more minority or mixed-race newborns
than non-Hispanic whites. Surely, this tipping point will effect the US
population for decades to come.
Additionally, the winter storm (with
its chilly reception by some) of the Patient Affordable Care Act of 2010
increases the number of insured in the US to 33 million in 2014, forty-three
percent of which will be from multicultural population segments.
Unlike the path of destruction Sandy
is currently cutting across the Eastern Seaboard, this perfect storm creates a
tremendous opportunity for pharmaceutical companies. A whole new influx
of consumers will suddenly be up for grabs and getting their attention will be
necessary for a company’s survival. Roughly 14 million non-English
speaking patients will require information on navigating new terrain created by
the Affordable Care Act.
Multicultural marketing budgets,
often considered optional and usually the first budget cut in recessions, will
be a necessary lifeline as multicultural consumers’ loyalty will go to those
who made the effort to reach them. Educating multicultural populations on
how to use the whirlwind of state specific online Health Benefits Exchanges for
buying insurance under the Act will give companies the lead in market share and
help them weather the new environment in which the pharmaceutical industry now
operates.
Sherry Dineen
No comments:
Post a Comment